SCHEMBL960217

SCHEMBL960217

C[C@H](N)CC#N

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL962192 1.00
SCHEMBL328810 1.00
Hydrochloric Acid SCHEMBL21175423 0.97
Hydrochloric Acid SCHEMBL292019 0.97
Nitric Acid SCHEMBL14696431 0.81 CA5A (0.35)
SCHEMBL31472174 0.79
Trifluoroacetic Acid SCHEMBL4331701 0.78 DPP4 (0.37)
SCHEMBL12868512 0.75
SCHEMBL11632373 0.75
SCHEMBL1345692 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119913220-A Method for preparing GLP-1 receptor agonist intermediate 宁波酶赛生物工程有限公司 2025-05-02 CN claimed
EP-2763990-B1 PYRROLOPYRAZINE KINASE INHIBITORS HOFFMANN LA ROCHE (CH) 2017-02-22 EP claimed
US-8658646-B2 Pyrrolopyrazine kinase inhibitors HOFFMANN-LAROCHE INC. (US) 2014-02-25 US claimed
US-20260103463-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2026-04-16 US disclosed
US-20260055105-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2026-02-26 US disclosed
US-12410168-B2 Pyrazolopyridine derivative having GLP-1 receptor agonist effect CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-09-09 US disclosed
US-12331049-B2 Pyrazolopyridine derivative having GLP-1 receptor agonist effect CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-06-17 US disclosed
US-12331050-B2 Pyrazolopyridine derivative having GLP-1 receptor agonist effect CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-06-17 US disclosed
US-RE50455-E1 Pyrazolopyridine derivative having GLP-1 receptor agonist effect CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-06-10 US disclosed
CN-119913220-A Method for preparing GLP-1 receptor agonist intermediate 宁波酶赛生物工程有限公司 2025-05-02 CN disclosed
EP-4097099-B9 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO INC (US) 2025-04-30 EP disclosed
US-20060106061-A1 PGD2 receptor antagonists for the treatment of inflammatory diseases MILLENNIUM PHARMACEUTICALS, INC. 2006-05-18 US disclosed
CN-1720047-A PgD2 receptor antagonists for the treatment of inflammatory diseases MILLENNIUM PHARM INC (US) 2006-01-11 CN disclosed
US-20050277670-A1 Chemokine receptor binding compounds ANORMED INC. 2005-12-15 US disclosed
US-20050256158-A1 PGD2 receptor antagonists for the treatment of inflammatory diseases MILLENNIUM PHARMACEUTICALS, INC. 2005-11-17 US disclosed
WO-2005100321-A1 PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-10-27 WO disclosed
EP-1556047-A2 PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-07-27 EP disclosed
WO-2005059107-A2 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED INC. (CA) 2005-06-30 WO disclosed
US-20040082609-A1 PGD2 receptor antagonists for the treatment of inflammatory diseases MILLENNIUM PHARMACEUTICALS, INC. 2004-04-29 US disclosed
WO-2004032848-A2 PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES MILLENNIUM PHARMACEUTICALS, INC. (US) 2004-04-22 WO disclosed